Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash & Current Investments (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Cash & Current Investments for 14 consecutive years, with $28.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 51.68% year-over-year to $28.6 million, compared with a TTM value of $28.6 million through Dec 2025, down 51.68%, and an annual FY2025 reading of $28.6 million, down 51.68% over the prior year.
  • Cash & Current Investments was $28.6 million for Q4 2025 at Heron Therapeutics, down from $55.5 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $257.7 million in Q2 2021 and bottomed at $26.7 million in Q2 2025.
  • Average Cash & Current Investments over 5 years is $84.5 million, with a median of $58.2 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments crashed 68.79% in 2023, then skyrocketed 61.1% in 2024.
  • Year by year, Cash & Current Investments stood at $71.5 million in 2021, then grew by 18.61% to $84.9 million in 2022, then tumbled by 32.79% to $57.0 million in 2023, then grew by 3.95% to $59.3 million in 2024, then tumbled by 51.68% to $28.6 million in 2025.
  • Business Quant data shows Cash & Current Investments for HRTX at $28.6 million in Q4 2025, $55.5 million in Q3 2025, and $26.7 million in Q2 2025.